{"protocolSection":{"identificationModule":{"nctId":"NCT07108153","orgStudyIdInfo":{"id":"SION-719-201"},"organization":{"fullName":"Sionna Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta","officialTitle":"A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed TrikaftaÂ® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation","acronym":"PreciSION CF"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-11-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-18","studyFirstSubmitQcDate":"2025-07-31","studyFirstPostDateStruct":{"date":"2025-08-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-19","lastUpdatePostDateStruct":{"date":"2025-12-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sionna Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta."},"conditionsModule":{"conditions":["Cystic Fibrosis (CF)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":16,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","type":"EXPERIMENTAL","description":"Participants receive SION-719 for one treatment period, and placebo to match SION-719 for the other treatment period. All participants will remain on their physician-prescribed Trikafta as background therapy throughout the study.","interventionNames":["Drug: SION-719","Drug: Placebo-to-match SION-719"]},{"label":"Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719","type":"EXPERIMENTAL","description":"Participants receive placebo to match SION-719 for one treatment period and SION-719 for the other treatment period. All participants will remain on their physician-prescribed Trikafta as background therapy throughout the study.","interventionNames":["Drug: SION-719","Drug: Placebo-to-match SION-719"]}],"interventions":[{"type":"DRUG","name":"SION-719","description":"All participants receive SION-719, as specified by their treatment sequence assignment","armGroupLabels":["Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719"]},{"type":"DRUG","name":"Placebo-to-match SION-719","description":"All participants receive placebo to match SION-719, as specified by their treatment sequence assignment","armGroupLabels":["Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed Trikafta","description":"Adverse events will be assessed by Common Terminology Criteria for Adverse Events (CTCAE), v. 5.0","timeFrame":"Day 1 through day 57"}],"secondaryOutcomes":[{"measure":"Change from baseline in sweat chloride levels","description":"Changes from baseline in sweat chloride levels will be analyzed with mixed model repeated measures (MMRM) methods.","timeFrame":"Baseline to Day 15 in each treatment period"},{"measure":"Concentration of SION-719 in plasma and change of concentration of SION-719 in plasma.","description":"Concentrations of plasma SION-719 will be evaluated at each collected timepoint and summarized using descriptive statistics.","timeFrame":"Day 1 through day 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of CF with F508del homozygous genotype based on documented CFTR genotype laboratory report.\n* Adherent to physician-prescribed Trikafta, as assessed by the Investigator, for at least 3 months prior to the Screening visit, taken at the recommended dose without modifications and on the regimen described in the current prescribing information.\n* Stable CF disease without pulmonary exacerbation within 28 days before Baseline or acute non-CF-related illness within 14 days before Baseline.\n\nExclusion Criteria:\n\n* Participant has clinically significant current or recurrent illness, other than CF\n* Participant has a history of malignancy, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence for at least 1 year.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"VP, Head of Medical Affairs & Patient Advocacy","role":"CONTACT","phone":"617-819-1389","email":"medinfo@sionnatx.com"}],"overallOfficials":[{"name":"Medical Director","affiliation":"Sionna Therapeutics Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"National Jewish Health","status":"RECRUITING","city":"Denver","state":"Colorado","zip":"80206","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"University of Iowa","status":"RECRUITING","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Johns Hopkins","status":"RECRUITING","city":"Baltimore","state":"Maryland","zip":"21205","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Boston Children's Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Washington University","status":"RECRUITING","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"New York Medical College","status":"RECRUITING","city":"Hawthorne","state":"New York","zip":"10532","country":"United States","geoPoint":{"lat":41.10732,"lon":-73.79597}},{"facility":"Columbia University","status":"RECRUITING","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University Hospital of Cleveland","status":"RECRUITING","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Medical University of South Carolina","status":"RECRUITING","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Royal Prince Alfred Hospital","status":"RECRUITING","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Gold Coast University Hospital","status":"RECRUITING","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Monash University","status":"NOT_YET_RECRUITING","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"}],"ancestors":[{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D007232","term":"Infant, Newborn, Diseases"}]}},"hasResults":false}